threonine and carfilzomib

threonine has been researched along with carfilzomib in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (90.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M1
Appel, A1
Gallastegui, N; Groll, M1
Hu, Y; Wu, P; Zhang, J1
Hiepe, F; Radbruch, A1
Kłoczko, J; Ołdziej, AE; Romaniuk, W; Zińczuk, J1
Bocchia, M; Brambilla, CZ; Candi, V; Gozzetti, A; Papini, G; Sirianni, S1
Hasinoff, BB; Patel, D1
Hawkins, CJ; Patatsos, K; Shekhar, TM1
Agha, A; Ali, AA; Debiec-Rychter, M; Dhillon, HS; Duensing, A; Gebreyohannes, YK; Lee, DM; Makielski, KR; Mehalek, KR; Patil, SS; Rausch, JL; Schöffski, P; Tolstov, Y; Wellens, J; Wozniak, A1

Reviews

5 review(s) available for threonine and carfilzomib

ArticleYear
Novel proteasome inhibitors to overcome bortezomib resistance.
    Journal of the National Cancer Institute, 2011, Jul-06, Volume: 103, Issue:13

    Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination

2011
Clinical and marketed proteasome inhibitors for cancer treatment.
    Current medicinal chemistry, 2013, Volume: 20, Issue:20

    Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine

2013
Plasma cells as an innovative target in autoimmune disease with renal manifestations.
    Nature reviews. Nephrology, 2016, Volume: 12, Issue:4

    Topics: Autoantibodies; Autoimmune Diseases; B-Lymphocytes; Boronic Acids; Bortezomib; Glomerulonephritis; Humans; Immunologic Memory; Immunosuppressive Agents; Kidney Diseases; Lupus Nephritis; Oligopeptides; Peptides; Plasma Cells; Proteasome Inhibitors; Threonine

2016
[Proteasome inhibitors in cancer therapy].
    Postepy higieny i medycyny doswiadczalnej (Online), 2015, Dec-31, Volume: 69

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Dipeptides; Humans; Lactones; Multiple Myeloma; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrroles; Thiazoles; Threonine

2015
Second Generation Proteasome Inhibitors in Multiple Myeloma.
    Anti-cancer agents in medicinal chemistry, 2017, Volume: 17, Issue:7

    Topics: Animals; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Drug Discovery; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles; Threonine

2017

Other Studies

5 other study(ies) available for threonine and carfilzomib

ArticleYear
Drugs: More shots on target.
    Nature, 2011, Dec-14, Volume: 480, Issue:7377

    Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine

2011
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
    Methods in molecular biology (Clifton, N.J.), 2012, Volume: 832

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Saccharomyces cerevisiae; Threonine

2012
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
    Cardiovascular toxicology, 2018, Volume: 18, Issue:6

    Topics: Animals; Animals, Newborn; Boron Compounds; Boronic Acids; Bortezomib; Cardiotoxicity; Cell Survival; Dose-Response Relationship, Drug; Epoxy Compounds; Glycine; Humans; K562 Cells; Ketones; Kinetics; Myocytes, Cardiac; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Rats, Sprague-Dawley; Threonine

2018
Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
    Veterinary and comparative oncology, 2018, Volume: 16, Issue:4

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Bone Neoplasms; Boron Compounds; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Dog Diseases; Dogs; Doxorubicin; Glycine; Humans; Oligopeptides; Osteosarcoma; Proteasome Inhibitors; Sulfonamides; Threonine

2018
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.
    Scientific reports, 2020, 03-20, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Boronic Acids; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Glycine; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Oligopeptides; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction; Threonine; Xenograft Model Antitumor Assays

2020